EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Hookipa Pharma priced its IPO at $14 (€12) a share, setting it up to raise $84 million. The money will enable Hookipa to take a cytomegalovirus infection candidate through phase 2. Release 

> Affimed provided the FDA with information it hopes will lead to the lifting of the clinical hold on AFM11. The German biotech expects to receive an update from the FDA in the second quarter. Statement 

> Cassiopea posted 12-month data from a phase 2 trial of androgenic alopecia treatment Breezula. The trial met one of its two co-primary endpoints. Release 

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

> Silence Therapeutics named Giles Campion as head of R&D and chief medical officer. Campion was CMO at DMD biotech Prosensa at the time of its acquisition by BioMarin Pharmaceutical. Statement

> GenSight Biologics posted 72-week data from a Leber hereditary optic neuropathy gene therapy phase 3 trial. Release 

> Mereo BioPharma revealed it has wrapped up an end-of-phase 2 meeting with the FDA. The company thinks the regulatory progress will help with partnering discussions about chronic obstructive pulmonary disease prospect acumapimod. Statement 

Suggested Articles

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.

Annexon Biosciences and AlloVir are seeking a $100 million IPO apiece in a buoyant market that shows no signs of slowing down.